PTJ
LGND icon

Paul Tudor Jones’s Ligand Pharmaceuticals LGND Stock Holding History

Paul Tudor Jones’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,622
Closed -$414K – 2709
2023
Q1 		$414K Sell
5,622
-4,322
-43% -$307K 0.01% 1729
2022
Q4 		$664K Buy
+9,944
New +$647K 0.01% 1401
2022
Q1 		– Sell
-5,311
Closed -$512K – 2384
2021
Q4 		$512K Buy
+5,311
New +$491K 0.01% 1450
2021
Q2 		– Sell
-5,343
Closed -$508K – 1776
2021
Q1 		$508K Sell
5,343
-17,320
-76% -$1.64M 0.01% 1132
2020
Q4 		$1.41M Buy
22,663
+14,021
+162% +$799K 0.04% 561
2020
Q3 		$514K Buy
+8,642
New +$590K 0.02% 808
2020
Q1 		– Sell
-9,277
Closed -$604K – 1200
2019
Q4 		$604K Buy
9,277
+5,532
+148% +$370K 0.03% 658
2019
Q3 		$233K Sell
3,745
-24,402
-87% -$1.53M 0.01% 928
2019
Q2 		$2M Buy
28,147
+9,894
+54% +$729K 0.06% 331
2019
Q1 		$1.43M Sell
18,253
-30,529
-63% -$2.31M 0.06% 354
2018
Q4 		$4.13M Buy
+48,782
New +$5.2M 0.08% 72
2018
Q3 		– Sell
-8,534
Closed -$1.1M – 1175
2018
Q2 		$1.1M Buy
8,534
+5,961
+232% +$665K 0.04% 408
2018
Q1 		$265K Buy
+2,573
New +$254K 0.01% 781
2016
Q4 		– Sell
-3,687
Closed -$235K – 1519
2016
Q3 		$235K Sell
3,687
-3,366
-48% -$247K 0.01% 1168
2016
Q2 		$525K Buy
7,053
+801
+13% +$59.4K 0.01% 803
2016
Q1 		$418K Buy
6,252
+2,296
+58% +$140K 0.01% 1082
2015
Q4 		$268K Buy
+3,956
New +$244K 0.01% 1280
2014
Q4 		– Sell
-8,336
Closed -$244K – 1535
2014
Q3 		$244K Buy
+8,336
New +$277K 0.01% 1116
2014
Q2 		– Sell
-6,816
Closed -$286K – 1247
2014
Q1 		$286K Buy
+6,816
New +$284K 0.01% 842
2013
Q4 		– Sell
-18,755
Closed -$506K – 1320
2013
Q3 		$506K Buy
+18,755
New +$528K 0.02% 339

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Paul Tudor Jones's LGND Position: Q2 2023 in Review

Paul Tudor Jones sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 5,622 shares — an estimated $414K sold.

Paul Tudor Jones first reported a position in LGND in Q3 2013 and held it in 20 quarters. The position peaked at $4.13M in Q4 2018. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Paul Tudor Jones reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Paul Tudor Jones sold 5,622 Ligand Pharmaceuticals shares in Q2 2023, an estimated $414K.
  • Paul Tudor Jones first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 20 quarters.
  • Paul Tudor Jones's Ligand Pharmaceuticals position peaked at $4.13M in Q4 2018.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.